Report Preview

Yellow Fever Treatment Market

The global yellow fever treatment market size was valued at USD 470 million in 2021 and is projected to reach around USD 650 million in 2030 exhibiting a CAGR of 3.8% in the forecasted period. The unhealthy lifestyle of people boosts the susceptibility of yellow fever across the world is expected to upsurge the market growth. Moreover, improving healthcare organization in developing nations and increasing awareness among the people regarding the management of yellow fever is further assessed to bolster the growth of the yellow fever treatment market. However, the factors such as inaccessibility of an actual treatment options other than vaccination and inadequate supply of vaccination to encounter the growing demand anticipated to confine the market growth rate.

Increasing research and development for the development of vaccines for yellow fever is estimated to boost growth of the global yellow fever treatment market throughout the forecasted period. For instance, Saint Louis University’s Center for Vaccine Development had introduced inspecting a vaccine for yellow fever in July 2021. Sanofi Pasteur subsidized this research and there is a need for increasing a new vaccine as the vaccine presently used consists of egg protein which cannot be used for individuals allergic to egg.

The pandemic has obstructed clinical trials, as many of them have been stopped owing to COVID-19. Scientists are facing huge challenges in carrying out clinical trials. Giving raw materials for the manufacture of drugs due to disruptions in transport systems is among the major problems faced by them. COVID-19 has had an adverse impact in countries such as India, Brazil and Pakistan, as it impacted the preventive measures in contradiction of vector-borne diseases. Owing to COVID-19, a reduction in vaccination rate of measles and yellow fever was observed in 2020.

Moreover, augmented support from several administrations for carrying out vaccination in large numbers is anticipated to boost growth of the global yellow fever treatment market during the forecasted period. For example, the GAVI Alliance, has financed more than US$ 500 million since 2001, for monitoring the spread of yellow fever and they are directing to protect lives by booming out immunization of individuals. They focus mostly on the African countries as majority of deaths occur because of yellow fewer.

Transmission Type Insights

Based on the transmission type, the yellow fever treatment market is segmented into intermediate yellow fever, sylvatic yellow fever, urban yellow fever, and others. In 2021, the intermediate yellow fever segment led the market with the major market share of 27%. The Intermediate yellow fever virus is an arbovirus part of the flavivirus genus. These mosquitoes belong to the Aedes and Haemogogus classes and are the virus carriers. Moreover, the growing demand for the growth of arbovirus propels the segment’s growth.

Medication Insights

Based on medication, the yellow fever treatment market is segmented into proton pump inhibitors, antipyretics, histamine H2 antagonists, and others. In 2021, the proton pump inhibitor dominated the market with the maximum market share of 31%. The proton pump inhibitor has accounted for the major revenue in the market owing to the rising focus on inhibiting infection from one patient to another. Proton Pump Inhibitors have demonstrated helpful in handling yellow fever. Proton pump inhibitors offer fluids and oxygen, keep adequate blood pressure, substitute blood loss, if dialysis for kidney failure, and treat any further infections that develop.

End User Insights

Based on the end user, the yellow fever treatment market is categorized as specialty clinics, hospitals, homecare, and others. In 2021, the hospitals segment ruled the market with the largest market share of 30%. As hospitals are the major locations for handling yellow fever patients and further people are vaccinating against yellow fever owing to their augmented awareness, this market segment is anticipated to generate the most revenue.

Region Insights

In 2021, North America appeared as the largest market for the global yellow fever treatment market, with a market share of about 38%. Owing to the rising number of research and development activities shown by a variety of small and medium industries in North America to produce medical healthcare facilities, the market for yellow fever treatment has been increasing. Furthermore, the United States has sustained a low rate for its research and development tax credit, which adds to an increase in the market’s demand for yellow fever treatment.

However, the Asia Pacific market is anticipated to grow at the fastest CAGR between 2022 and 2030. The market for yellow fever in the region has been increasing due to the population growth, changes in lifestyle, and consumption of unhealthy food. The increase in government initiatives and healthcare infrastructure development plays a critical role in market growth. Moreover, the growing occurrences of yellow fever treatment in the region at the local clinics and hospitals boost the market’s growth.

Key Companies Insights

The market for yellow fever treatment is moderately competitive. With the rising applications of Yellow fever treatment, new players are considering to enter the market. The companies are also involved in activities like joint ventures, acquisitions, partnerships, mergers, and collaborations. These activities aid in growing the effect of the players in the yellow fever treatment market, ultimately boosting the market growth. Some of the key companies working in the global yellow fever treatment market include:

• Sanofi Pasteur SA
• Pfizer Inc.
• BIOCRYST PHARMACEUTICALS, INC.
• Tychan Pte. Ltd.
• Johnson & Johnson Services, Inc.
• Takeda Pharmaceutical Company Limited
• Bayer AG
• GlaxoSmithKline plc
• Bio-Manguinhos
• Institut Pasteur de Dakar
• FSUE Chumakov
• Other players

Some of the Recent Developments:

• In April 2022, Daewon Pharmaceutical launched Escorten to the Korean market. This medication was among the first proton-pump inhibitors available in the nation.
• In September 2021, researchers at the ‘Research Centre biotechnology of the Russian Academy of Sciences presented new technology, synthesized five chemicals, and used artificial intelligence to inspect the activity of these compounds. The elements that they selected were related with pyrazosulphonamide’s derivatives in some way.

Segments

By Transmission Type

• Intermediate Yellow Fever
• Sylvatic Yellow Fever
• Urban Yellow Fever
• Others

By Medication

• Proton Pump Inhibitors
• Antipyretics
• Histamine H2 Antagonists
• Others

By End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

By Geography

• North America
  • S.
  • Canada
  • Mexico
• Europe
  • K.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • ASEAN
• Latin America
  • Brazil
  • Argentina
  • Colombia
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Egypt